- Home
- ZVSA vs QLGN Comparison
ZVSA vs QLGN Comparison
Compare ZVSA & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- QLGN
- Stock Information
- Founded
- ZVSA 2014
- QLGN 1996
- Country
- ZVSA United States
- QLGN United States
- Employees
- ZVSA N/A
- QLGN N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- QLGN Health Care
- Exchange
- ZVSA Nasdaq
- QLGN Nasdaq
- Market Cap
- ZVSA 2.8M
- QLGN 2.5M
- IPO Year
- ZVSA N/A
- QLGN N/A
- Fundamental
- Price
- ZVSA $2.51
- QLGN $0.16
- Analyst Decision
- ZVSA Strong Buy
- QLGN
- Analyst Count
- ZVSA 1
- QLGN 0
- Target Price
- ZVSA $240.00
- QLGN N/A
- AVG Volume (30 Days)
- ZVSA 93.2K
- QLGN 337.7K
- Earning Date
- ZVSA 08-09-2024
- QLGN 08-14-2024
- Dividend Yield
- ZVSA N/A
- QLGN N/A
- EPS Growth
- ZVSA N/A
- QLGN N/A
- EPS
- ZVSA N/A
- QLGN N/A
- Revenue
- ZVSA N/A
- QLGN N/A
- Revenue This Year
- ZVSA N/A
- QLGN N/A
- Revenue Next Year
- ZVSA N/A
- QLGN N/A
- P/E Ratio
- ZVSA N/A
- QLGN N/A
- Revenue Growth
- ZVSA N/A
- QLGN N/A
- 52 Week Low
- ZVSA $2.50
- QLGN $0.14
- 52 Week High
- ZVSA $79.80
- QLGN $1.10
- Technical
- Relative Strength Index (RSI)
- ZVSA 38.18
- QLGN 32.97
- Support Level
- ZVSA $2.71
- QLGN $0.14
- Resistance Level
- ZVSA $2.89
- QLGN $0.22
- Average True Range (ATR)
- ZVSA 0.37
- QLGN 0.02
- MACD
- ZVSA 0.00
- QLGN -0.00
- Stochastic Oscillator
- ZVSA 0.00
- QLGN 21.12
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.